ALGN vs. NVO: A Head-to-Head Stock Comparison

Updated on August 30, 2025

Here’s a clear look at ALGN and NVO, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

ALGN is a standard domestic listing, while NVO trades as an American Depositary Receipt (ADR), offering U.S. investors access to its foreign-listed shares.

Symbol	ALGN	NVO
Company Name	Align Technology, Inc.	Novo Nordisk A/S
Country	United States	Denmark
GICS Sector	Health Care	Health Care
GICS Industry	Health Care Equipment & Supplies	Pharmaceuticals
Market Capitalization	10.29 billion USD	247.11 billion USD
Exchange	NasdaqGS	NYSE
Listing Date	January 30, 2001	April 30, 1981
Security Type	Common Stock	ADR

Historical Performance

This chart compares the performance of ALGN and NVO by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

ALGN vs. NVO: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

Symbol	ALGN	NVO
5-Day Price Return	0.93%	1.55%
13-Week Price Return	-20.48%	-23.14%
26-Week Price Return	-25.44%	-37.05%
52-Week Price Return	-38.71%	67.26%
Month-to-Date Return	10.05%	11.59%
Year-to-Date Return	-31.91%	-43.78%
10-Day Avg. Volume	1.29M	6.90M
3-Month Avg. Volume	1.33M	6.61M
3-Month Volatility	80.97%	64.95%
Beta	1.73	1.52

Profitability

Return on Equity (TTM)

ALGN

11.29%

Health Care Equipment & Supplies Industry

Max: 34.53%
Q3: 19.38%
Median: 9.52%
Q1: 4.86%
Min: -7.58%

ALGN’s Return on Equity of 11.29% is on par with the norm for the Health Care Equipment & Supplies industry, indicating its profitability relative to shareholder equity is typical for the sector.

NVO

77.86%

Pharmaceuticals Industry

Max: 38.59%
Q3: 19.84%
Median: 11.90%
Q1: 5.63%
Min: -9.96%

NVO’s Return on Equity of 77.86% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.

ALGN vs. NVO: A comparison of their Return on Equity (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Net Profit Margin (TTM)

ALGN

11.04%

Health Care Equipment & Supplies Industry

Max: 23.34%
Q3: 13.06%
Median: 9.53%
Q1: 5.96%
Min: -3.87%

ALGN’s Net Profit Margin of 11.04% is aligned with the median group of its peers in the Health Care Equipment & Supplies industry. This indicates its ability to convert revenue into profit is typical for the sector.

NVO

35.61%

Pharmaceuticals Industry

Max: 34.51%
Q3: 17.73%
Median: 12.12%
Q1: 5.99%
Min: -7.73%

NVO’s Net Profit Margin of 35.61% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates outstanding operational efficiency and a strong competitive advantage in converting revenue into profit.

ALGN vs. NVO: A comparison of their Net Profit Margin (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Operating Profit Margin (TTM)

ALGN

15.15%

Health Care Equipment & Supplies Industry

Max: 29.44%
Q3: 17.80%
Median: 13.95%
Q1: 8.73%
Min: -3.56%

ALGN’s Operating Profit Margin of 15.15% is around the midpoint for the Health Care Equipment & Supplies industry, indicating that its efficiency in managing core business operations is typical for the sector.

NVO

45.78%

Pharmaceuticals Industry

Max: 41.53%
Q3: 23.00%
Median: 16.24%
Q1: 9.24%
Min: -6.94%

NVO’s Operating Profit Margin of 45.78% is exceptionally high, placing it well above the typical range for the Pharmaceuticals industry. This demonstrates outstanding efficiency in managing its core operations, which can be a result of strong pricing power or superior cost control.

ALGN vs. NVO: A comparison of their Operating Profit Margin (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Profitability at a Glance

Symbol	ALGN	NVO
Return on Equity (TTM)	11.29%	77.86%
Return on Assets (TTM)	7.03%	24.22%
Net Profit Margin (TTM)	11.04%	35.61%
Operating Profit Margin (TTM)	15.15%	45.78%
Gross Profit Margin (TTM)	69.84%	83.95%

Financial Strength

Current Ratio (MRQ)

ALGN

1.23

Health Care Equipment & Supplies Industry

Max: 4.90
Q3: 3.05
Median: 2.14
Q1: 1.49
Min: 0.86

ALGN’s Current Ratio of 1.23 falls into the lower quartile for the Health Care Equipment & Supplies industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

NVO

0.78

Pharmaceuticals Industry

Max: 4.49
Q3: 2.77
Median: 1.74
Q1: 1.26
Min: 0.11

NVO’s Current Ratio of 0.78 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

ALGN vs. NVO: A comparison of their Current Ratio (MRQ) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Debt-to-Equity Ratio (MRQ)

ALGN

0.00

Health Care Equipment & Supplies Industry

Max: 1.49
Q3: 0.71
Median: 0.45
Q1: 0.14
Min: 0.00

Falling into the lower quartile for the Health Care Equipment & Supplies industry, ALGN’s Debt-to-Equity Ratio of 0.00 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.

NVO

0.59

Pharmaceuticals Industry

Max: 2.44
Q3: 1.07
Median: 0.42
Q1: 0.11
Min: 0.00

NVO’s Debt-to-Equity Ratio of 0.59 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

ALGN vs. NVO: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Interest Coverage Ratio (TTM)

ALGN

38.91

Health Care Equipment & Supplies Industry

Max: 58.29
Q3: 25.56
Median: 9.06
Q1: 3.60
Min: -28.92

ALGN’s Interest Coverage Ratio of 38.91 is in the upper quartile for the Health Care Equipment & Supplies industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.

NVO

149.07

Pharmaceuticals Industry

Max: 103.95
Q3: 44.18
Median: 9.83
Q1: 2.82
Min: -42.71

With an Interest Coverage Ratio of 149.07, NVO demonstrates a superior capacity to service its debt, placing it well above the typical range for the Pharmaceuticals industry. This stems from either robust earnings or a conservative debt load.

ALGN vs. NVO: A comparison of their Interest Coverage Ratio (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Financial Strength at a Glance

Symbol	ALGN	NVO
Current Ratio (MRQ)	1.23	0.78
Quick Ratio (MRQ)	1.06	0.56
Debt-to-Equity Ratio (MRQ)	0.00	0.59
Interest Coverage Ratio (TTM)	38.91	149.07

Growth

Revenue Growth

ALGN vs. NVO: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

ALGN vs. NVO: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

ALGN

0.00%

Health Care Equipment & Supplies Industry

Max: 4.05%
Q3: 1.76%
Median: 0.71%
Q1: 0.00%
Min: 0.00%

ALGN currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

NVO

3.30%

Pharmaceuticals Industry

Max: 6.98%
Q3: 3.32%
Median: 2.13%
Q1: 0.14%
Min: 0.00%

NVO’s Dividend Yield of 3.30% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.

ALGN vs. NVO: A comparison of their Dividend Yield (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Dividend Payout Ratio (TTM)

ALGN

0.00%

Health Care Equipment & Supplies Industry

Max: 160.00%
Q3: 72.47%
Median: 27.49%
Q1: 0.00%
Min: 0.00%

ALGN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

NVO

61.60%

Pharmaceuticals Industry

Max: 165.20%
Q3: 90.59%
Median: 49.13%
Q1: 28.91%
Min: 0.00%

NVO’s Dividend Payout Ratio of 61.60% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

ALGN vs. NVO: A comparison of their Dividend Payout Ratio (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Dividend at a Glance

Symbol	ALGN	NVO
Dividend Yield (TTM)	0.00%	3.30%
Dividend Payout Ratio (TTM)	0.00%	61.60%

Valuation

Price-to-Earnings Ratio (TTM)

ALGN

23.59

Health Care Equipment & Supplies Industry

Max: 73.48
Q3: 51.69
Median: 34.31
Q1: 25.74
Min: 11.47

In the lower quartile for the Health Care Equipment & Supplies industry, ALGN’s P/E Ratio of 23.59 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.

NVO

13.91

Pharmaceuticals Industry

Max: 42.51
Q3: 26.88
Median: 19.11
Q1: 15.12
Min: 0.00

In the lower quartile for the Pharmaceuticals industry, NVO’s P/E Ratio of 13.91 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.

ALGN vs. NVO: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Price-to-Sales Ratio (TTM)

ALGN

2.60

Health Care Equipment & Supplies Industry

Max: 9.53
Q3: 5.26
Median: 3.39
Q1: 2.13
Min: 0.00

ALGN’s P/S Ratio of 2.60 aligns with the market consensus for the Health Care Equipment & Supplies industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

NVO

4.95

Pharmaceuticals Industry

Max: 7.55
Q3: 4.54
Median: 2.11
Q1: 1.52
Min: 0.00

NVO’s P/S Ratio of 4.95 is in the upper echelon for the Pharmaceuticals industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.

ALGN vs. NVO: A comparison of their Price-to-Sales Ratio (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Price-to-Book Ratio (MRQ)

ALGN

3.51

Health Care Equipment & Supplies Industry

Max: 10.85
Q3: 5.98
Median: 3.48
Q1: 2.43
Min: 0.69

ALGN’s P/B Ratio of 3.51 is within the conventional range for the Health Care Equipment & Supplies industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

NVO

8.87

Pharmaceuticals Industry

Max: 9.78
Q3: 4.96
Median: 2.23
Q1: 1.46
Min: 0.60

NVO’s P/B Ratio of 8.87 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.

ALGN vs. NVO: A comparison of their Price-to-Book Ratio (MRQ) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Valuation at a Glance

Symbol	ALGN	NVO
Price-to-Earnings Ratio (TTM)	23.59	13.91
Price-to-Sales Ratio (TTM)	2.60	4.95
Price-to-Book Ratio (MRQ)	3.51	8.87
Price-to-Free Cash Flow Ratio (TTM)	16.34	23.46